Get notified when MNPR files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsMonopar presents Phase 2 Wilson disease trial results at major European liver conference
Filed May 29, 2026 · Period ending May 29, 2026 · ~1 min read
Key Changes
-
medium
Monopar presented Phase 2 study results for ALXN1840 (tiomolibdate choline) in Wilson disease patients at EASL International Liver Congress 2026, evaluating effects on liver pathology and clinical symptoms.
Item 8.01 view on EDGAR → -
medium
The study (NCT04422431) represents a key clinical milestone for the company's lead Wilson disease program, though specific efficacy and safety data are contained in the attached presentation rather than the filing itself.
8-K body view on EDGAR → -
low
Company filed presentation slides as Exhibit 99.1, which would contain the actual trial data and conclusions from the EASL conference.
Exhibit 99.1 view on EDGAR →
This preview is just the start — the full report includes the narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (NKE 10-K) is open in full — no account needed.
Partner
Trade MNPR commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jun 1, 2026 · How we verify